Reimbursement Review Reports

The latest Reimbursement Review reports are posted to this page. Our reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name Sort ascending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Zytram XL Tramadol hydrochloride Pain, acute Withdrawn
Zytram XL Tramadol hydrochloride Pain, acute Do not list Complete
Zytiga (Resubmission) Abiraterone Prostate Cancer Resubmission Withdrawn
Zytiga Abiraterone Withdrawn
Zytiga Abiraterone acetate Metastatic Castration Resistant Prostate Cancer Reimburse with clinical criteria and/or conditions Complete
Zykadia (Resubmission) Ceritinib metastatic non-small cell lung cancer Reimburse with clinical criteria and/or conditions Complete
Zykadia Ceritinib Metastatic Non-Small Cell Lung Cancer Do not reimburse Complete
Zydelig Idelalisib Chronic lymphocytic leukemia Reimburse with clinical criteria and/or conditions Complete
Zydelig Idelalisib Follicular Lymphoma Do not reimburse Complete
Zoryve roflumilast Plaque psoriasis Reimburse with clinical criteria and/or conditions Complete
Zolinza vorinostat Cutaneous T-cell lymphoma CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer Not filed
Zolgensma onasemnogene abeparvovec Spinal muscular atrophy (SMA), pediatrics Reimburse with clinical criteria and/or conditions Complete
Zinbryta Daclizumab beta Multiple Sclerosis, relapsing-remitting Reimburse with clinical criteria and/or conditions Complete
Zevalin iIbritumomab tiuxetan Non-Hodgkin’s Lymphoma (NHL) Unable to recommend reimbursement Not filed
Zepzelca lurbinectedin metastatic small cell lung cancer (SCLC) Do not reimburse Complete
Zeposia ozanimod Ulcerative colitis Reimburse with clinical criteria and/or conditions Complete
Zeposia ozanimod Multiple Sclerosis, relapsing - remitting Do not reimburse Complete
Zepatier Elbasvir/grazoprevir Hepatitis C, chronic Reimburse with clinical criteria and/or conditions Complete
Zenhale (inhalation aerosol) Mometasone furoate and formoterol Asthma Do not list Complete
Zenhale Mometasone/formoterol Asthma List with clinical criteria and/or conditions Complete
Zemaira Alpha1-proteinase inhibitor (Human) Severe Alpha1-proteinase inhibitor deficiency Reimburse with clinical criteria and/or conditions Complete
Zeldox Ziprasidone hydrochloride Schizophrenia and related psychotic disorders List with clinical criteria and/or conditions Complete
Zelboraf Vemurafenib Metastatic Melanoma Reimburse with clinical criteria and/or conditions Complete
Zejula Niraparib Ovarian Cancer Reimburse with clinical criteria and/or conditions Complete
Zejula Niraparib First Line OC Reimburse with clinical criteria and/or conditions Complete